Cancer Research Landon Prizes for Basic and Translational Cancer Research Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 52, 127-131, January 1, 1992]
© 1992 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chari, R. V. J.
Right arrow Articles by Goldmacher, V. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chari, R. V. J.
Right arrow Articles by Goldmacher, V. S.

Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs

Ravi V. J. Chari1, Bridget A. Martell, Jonathan L. Gross, Sherrilyn B. Cook, Sudhir A. Shah, Walter A. Blättler, Sara J. McKenzie and Victor S. Goldmacher1

ImmunoGen, Inc., Cambridge, Massachusetts 02139 [R. V. J. C., B. A. M., J. L. G., S. B. C., S. A. S., W. A. B., V. S. G.], and Applied bioTechnology, Cambridge, Massachusetts 02142 [S. J. M.]

The potential of immunoconjugates of cytotoxic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concentrations of these drugs to the target cells. In an effort to overcome this problem we have synthesized maytansinoids that have 100- to 1000-fold higher cytotoxic potency than clinically used anticancer drugs. These maytansinoids are linked to antibodies via disulfide bonds, which ensures the release of fully active drug inside the cells. The conjugates show high antigen-specific cytotoxicity for cultured human cancer cells (50% inhibiting concentration, 10 to 40 pM), low systemic toxicity in mice, and good pharmacokinetic behavior.

1 To whom requests for reprints should be addressed, at ImmunoGen, Inc., 148 Sidney Street, Cambridge, MA 02139.

Received 8/ 7/91. Accepted 10/22/91.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. Ostermann, P. Garin-Chesa, K. H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W. J. Rettig, and G. R. Adolf
Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts
Clin. Cancer Res., July 15, 2008; 14(14): 4584 - 4592.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. D. Galsky, M. Eisenberger, S. Moore-Cooper, W. K. Kelly, S. F. Slovin, A. DeLaCruz, Y. Lee, I. J. Webb, and H. I. Scher
Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
J. Clin. Oncol., May 1, 2008; 26(13): 2147 - 2154.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Reddy, E. Westrick, H. K.R. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V.J. Chari, V. S. Goldmacher, and C. P. Leamon
Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate
Cancer Res., July 1, 2007; 67(13): 6376 - 6382.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Chen, H. J. Millar, F. L. McCabe, C. D. Manning, R. Steeves, K. Lai, B. Kellogg, R. J. Lutz, M. Trikha, M. T. Nakada, et al.
{alpha}v Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models
Clin. Cancer Res., June 15, 2007; 13(12): 3689 - 3695.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. M. Tijink, J. Buter, R. de Bree, G. Giaccone, M. S. Lang, A. Staab, C. R. Leemans, and G. A.M.S. van Dongen
A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus.
Clin. Cancer Res., October 15, 2006; 12(20): 6064 - 6072.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. K. Erickson, P. U. Park, W. C. Widdison, Y. V. Kovtun, L. M. Garrett, K. Hoffman, R. J. Lutz, V. S. Goldmacher, and W. A. Blattler
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Cancer Res., April 15, 2006; 66(8): 4426 - 4433.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. V. Kovtun, C. A. Audette, Y. Ye, H. Xie, M. F. Ruberti, S. J. Phinney, B. A. Leece, T. Chittenden, W. A. Blattler, and V. S. Goldmacher
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
Cancer Res., March 15, 2006; 66(6): 3214 - 3221.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. D. Austin, X. Wen, L. Gazzard, C. Nelson, R. H. Scheller, and S. J. Scales
Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates
PNAS, December 13, 2005; 102(50): 17987 - 17992.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Tassone, V. S. Goldmacher, P. Neri, A. Gozzini, M. A. Shammas, K. R. Whiteman, L. L. Hylander-Gans, D. R. Carrasco, T. Hideshima, R. Shringarpure, et al.
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
Blood, December 1, 2004; 104(12): 3688 - 3696.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland
A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer
Cancer Res., November 1, 2004; 64(21): 7995 - 8001.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, et al.
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Clin. Cancer Res., October 15, 2004; 10(20): 7063 - 7070.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson, et al.
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells
Cancer Res., July 1, 2004; 64(13): 4629 - 4636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. R. Helft, R. L. Schilsky, F. J. Hoke, D. Williams, H. L. Kindler, E. Sprague, M. DeWitte, H. K. Martino, J. Erickson, L. Pandite, et al.
A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors
Clin. Cancer Res., July 1, 2004; 10(13): 4363 - 4368.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Xie, C. Audette, M. Hoffee, J. M. Lambert, and W. A. Blattler
Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1073 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. W. Tolcher, L. Ochoa, L. A. Hammond, A. Patnaik, T. Edwards, C. Takimoto, L. Smith, J. de Bono, G. Schwartz, T. Mays, et al.
Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study
J. Clin. Oncol., January 15, 2003; 21(2): 211 - 222.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. T. Sandlund, J. R. Downing, and W. M. Crist
Non-Hodgkin's Lymphoma in Childhood
N. Engl. J. Med., May 9, 1996; 334(19): 1238 - 1248.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.